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Existing chemotaxis assays do not generate stable chemotactic gradients and thus—over time—functionally measure only
nonspecificrandommotion(chemokinesis).Incomparison,microfluidictechnologyhasthecapacitytogenerateatightlycontrolled
microenvironmentthatcanbestablymaintainedforextendedperiodsoftimeandis,therefore,amenabletoadaptationforassaying
chemotaxis. We describe here a novel microfluidic device for sensitive assay of cellular migration and show its application for
evaluating the chemotaxis of smooth muscle cells in a chemokine gradient.
1. Introduction
Directed cell migration plays a critical role in inflamma-
tory disorders, vascular disease, wound healing, and tumor
metastasis [1–5]. A number of in vitro approaches have
been developed to quantify cell migration, including closure
of monolayer wounds (“scratch assay”) and the Boyden
chamber[6–8].However,thesecurrentmethodsarerelatively
insensitive.Moreover,suchapproachesmayactuallymeasure
only chemokinesis, that is, increased random motion, rather
than chemotaxis—directed cell migration.
Indeed, the utility of the scratch assay and Boyden
chamber transwells [9, 10] is limited by their methodologic
design.
For the scratch assay, a defined “wound” (scratch) is
made in a confluent cell monolayer; cells at the edges of
the defect then progressively fill in the void, and the time
to restored confluence is quantified. Faster repair of the
scratchhasbeeninterpretedtoreflectenhanced“chemotaxis”
d u et oc e l lm a n i p u l a t i o no rt h en a t u r eo fs o l u b l ea g e n t s
added to the medium. While the experiment is conceptually
straightforward and technically easy to perform, the cells are
bathed in a uniform concentration of agent, and there is
no chemoattractant concentration gradient during the entire
experiment; the movement that fills in the gap therefore
represents only a “random walk.” Thus, the “migration”
i nas c r a t c ha s s a yi sl a r g e l yaf u n c t i o no fo n l yi n c r e a s e d
chemokinesis. Moreover, as typically performed—especially
over several hours of a prolonged assay—the closing of a
scratch“wound”alsolikelyincludesasubstantialcomponent
of cell proliferation.
The other most common method to measure “chemo-
taxis” involves the use of Boyden chamber transwells. Dif-
ferent concentrations of specific chemokines are placed in
the lower compartment of the device, while the cells to be
evaluated are incubated in the upper insert; a microporous
membrane separates the two chambers and forms a support
f o rc e l lg r o w t ha n dap a r t i a lb a r r i e rf o rm i g r a t i o n .C e l l s
that are counted at the lower face of the membrane, or that
accumulate in the lower chamber, are typically assessed at
a single fixed end point. This assay has the advantage of an
apparent directed migration, that is, from upper to lower
chamber but is still problematic. First, there is no “gradient”
of chemokines from top to bottom but rather only a single
step function from low to high concentrations. Second, there
isnowaytosustainthechemokinedifferentialfromthetopto2 BioMed Research International
bottomchambers[11].Initially,thechemokineconcentration
in the lower compartment is greater but within minutes
to hours, the concentrations equalize due to diffusion, at
which point specific chemotaxis ceases. Instead, long-term
measurements more likely reflect a significant element of
chemokinesis. Moreover, once cells fall through the mem-
braneandin tothelo werchamber ,thereisnoopportunityfor
reversemigration.Finally,theBoydenchamberisalsolimited
becausecellcountingrequiresterminationoftheexperiment;
a time course therefore requires multiple devices.
Microfluidic technology can overcome these limitations
by generating a long-term stable and controllable gradient
of soluble factors that can be continuously monitored over
time [12–16]. Using cells that have been treated to block
proliferation, such a device allows a true ongoing assessment
of chemotaxis versus chemokinesis. Figure 1 depicts such
a device where the source and sink concentrations are
maintained by creating corresponding wells whose volumes
a r el a r g er e l a t i v et ot h ed i ff u s i v efl u xt h r o u g ht h ec o n n e c t i n g
hydrogel channel [17]. At steady state, a linear concentration
gradient forms between these two wells. Although interstitial
flow through the hydrogel region can disrupt the gradient
if the hydrostatic pressures in the two wells are not equal,
pressure gradients are eliminated by connecting the source
and sink wells with additional channels and reservoirs that
serve as low resistance pathways for fluid flow and pressure
equilibration. Gradients can, thus, be maintained for several
days and used to study cell migration in a sensitive and
specific way with a variety of cell types [17]. The work
presented here describes the use of such devices to assess
chemotaxis for primary cultures of smooth muscle cells and
to compare it with scratch and Boyden chamber techniques
for sensitivity.
2. Materials and Methods
2.1. Primary Smooth Muscle Cells (SMC) Culture. Aortas
wereharvestedfrom8-week-oldC57/B6mice(CharlesRiver,
Wilmington, MA) with sterile dissecting scissors. Adherent
fatwasremoved,andaortaswereincubatedfor20minat37
∘C
in Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen,
GrandIsland,NY)containing1%penicillin/streptomycin,2%
fetal bovine serum, and 5mg/mL collagenase type II (Invit-
rogen).Aortaswererinsedincold DMEM andtheadventitia
was carefully dissected away; they were then cut into small
piecesandincubatedfor30minat37
∘CinDMEMcontaining
1mg/mL collagenase type I (Invitrogen) and 0.125mg/mL
elastase type III (Sigma-Aldrich, St.Louis, MO). Following
repeated pipetting to dissociate the tissue, the resulting cell
mixture was suspended in fresh “SMC medium” (DMEM
with 10% fetal bovine serum, 1% penicillin/streptomycin;
2% nonessential amino acids, 1% L-glutamine; all reagents
from Invitrogen) and grown at 37
∘Ci na5 %C O 2 incubator
on plates coated with 1mg/mL fibronectin for 30 minutes.
Once cell culture is established (typically after the first
passage),SMCaregrownonuncoatedplasticflasks(Corning
Incorporated, Corning, NY).
SMC were used from passages 2 to 7 and were 99.5%
pure as assessed by flow cytometry after staining for smooth
muscle 𝗼-actin. For staining, cells are harvested and fixed
with 1% paraformaldehyde (Sigma-Aldrich) in phosphate
buffered saline (PBS). FITC-conjugated antismooth muscle
𝗼-actin antibody (Sigma-Aldrich) at 1:100 dilution in 10X
BDperm/washbuffer(BDPharmingen,SanJose,California)
was applied for 10min at room temperature. Cells are washed
twice with 1% fetal bovine serum in PBS and once with 1%
fetal bovine serum in PBS containing 1% formaldehyde and
immediately analyzed by flow cytometry (FACScalibur, BD
Biosciences, San Jose, CA). FITC-conjugated mouse IgG1
i s o t y p e( B DP h a r m i n g e n )i su s e da sa ni s o t y p ec o n t r o l .
Cells for chemotactic assays were harvested when they had
achieved confluence.
2.2. Mitomycin-C Treatment. Cells were trypsinized (0.25%
trypsin-EDTA; Invitrogen) for 2min at 37
∘C, washed with
SMCmedium,andthenincubatedasasingle-cellsuspension
in 40𝜇g/mL mitomycin-C (MMC; Sigma-Aldrich) in SMC
medium for 30min at 37
∘C. After two additional washes
in PBS, cells were assessed for viability, proliferation, or
migratory capacity. For the wound healing (scratch) assay,
MMC treatment was performed after SMC plating and when
cells were 100% confluent; cells were incubated in 40𝜇g/mL
MMC in SMC medium for 30min at 37
∘Ca n dt h e nw a s h e d
t w i c ei nP B Sb e f o r ea s s a y .
2.3. SMC Proliferation Inhibition Assay. After MMC treat-
ment or control incubation in SMC medium, SMC were
cultured in 6-well plates (Corning Incorporated). Cells were
recovered after 1h, 24h, or 48h by trypsinization and cell
numbers and viability were assessed by counting using a
hemocytometer and trypan blue exclusion.
2.4. Wound Healing/Scratch Assay. SMC were cultured in 12-
well plates (Corning Incorporated) until confluent and then
t r e a t e dw i t hM M C .A ft e rw a s h i n g ,f r e s hS M Cm e d i u mw a s
addedandthecellmonolayerwasscratchedinareproducible
wayusingasterile200𝜇Lpipettetip.Differentconcentrations
of platelet-derived growth factor (PDGF; R&D Systems,
Minneapolis, MN) in SMC media were added to each well.
The distance between the edges of the scratch defect were
measured and averaged from five separate points at 3, 6, and
9h, or until the wound defect had closed.
2.5. Boyden Chamber Transwell Assay. 100𝜇Lo fS M Cs u s -
pensions at 1.0–1.5 × 10
5 cells/mL (1.0–1.5 × 10
4 total cells)
were loaded into the upper transwell inserts (Costar, Corn-
ing Incorporated) and 600𝜇L of SMC media containing
different concentrations of PDGF were placed in the lower
compartment. After 6h, 12h, or 24h of incubation, the
transwell membrane was stained with Hoechst 33342 (Invit-
rogen) according to the manufacturer’s recommendation,
and transmigrated cells on the lower face were counted on a
fluorescence microscope using MetaMorph NX Microscopy
Automation and Image Analysis Software (BioCompare,
South San Francisco, CA). No cells were ever identified in
the medium in the lower chamber. In experiments to assess
whether cell migration represented chemotaxis or randomBioMed Research International 3
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Figure 1: Device design and stability of concentration gradients as a function of time. (a) The lower 3 wells are cell and/or source wells for
chemokines,andtheupper3wellsserveasreservoirstomaintainequivalentpressuresinthelowerwells.Dependingonexperimentaldesign,
thesidewellsorthecentralwellcanserveassourcewells;cellsinacentralwellcanmigratetowarddifferentchemokinestimulioneitherside,
or different cell populations in the side wells can migrate towards a central chemokine stimulus. (b, c) Concentration gradients are shown
schematically after the addition of a low molecular weight fluorescent dye indicator to the source well and source reservoir, at either 2 hours
(b) or 72 hours (c). (d) Graphical display of concentration gradients from 0 hour through 72h after fluorescent dye addition to source well
and reservoir.
chemokinesis in the absence of a concentration gradient,
platelet derived growth factor-BB (PDGF) was added to the
lower chamber, top insert well only, or both top insert and
lower chamber.
2.6.MicrofluidicDeviceAssay. Themicrofluidicdevices(Fig-
ures 1(a)–1(c)) are prepared as described elsewhere [17].
As shown in Figure 1(d), gradients of added reagents are
stable for at least 72h. Depending on the experimental
protocol, cells to be evaluated are placed in the central
well and different chemotactic gradients developed from the
two side wells. Alternatively, the migration of two different
p o p u l a t i o n so fc e l l sc a nb ee v a l u a t e df r o mt h es i d ew e l l s ,
experiencing identical concentration gradients generated by
reagents placed in the central well. Cell concentrations
were always 4-5 × 10
5/mL and 40𝜇L of the cell suspensions
(1.6–2.0 × 10
3 cells) was loaded into test wells.
Cells were incubated in the devices for various time
points and then stained with Hoechst 33342 (Invitrogen).
The location of each cell was determined using fluorescence
microscopy (Nikon Eclipse TE2000-U; Nikon Instruments,
Inc., Melville, NY), and the distance migrated was assessed
using the Matlab program (MathWorks, Natick, MA). “Total
migration” is defined as the sum of the distances migrated4 BioMed Research International
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Figure 2: Assessment of cell migration in microfluidic devices. Cells were plated in the central lower well of a microfluidic device, with
50ng/mL PDGF in SMC medium placed in the left lower well and SMC medium alone placed in the right lower well, followed by incubation
at 37
∘C for 48h. (a, b) Phase contrast image of cell chemotaxis from the central channel in the direction of the 50ng/mL PDGF in the left
channel; the images are split along the channel between the sink and source wells so that the full length of the channel can be shown at a
magnificationsufficienttopermitcellularresolution.(c,d)Phasecontrastimageofcellchemokinesisfromthecentralchannelinthedirection
of SMC medium only. (e, f) Low-power fluorescence image of the left (e) or right; (f) channel at 48h after staining with Hoechst 33342. (g)
High-power fluorescence image of the left channel in panel (e); the black square without cells near the right-hand side of the image (asterisk)
is a structural post that marks the start point for the migration. (h) Example of the migration analysis. A vertical red line denotes the start
point; the distance from the start point to the center of each cell nucleus is measured, and the sum of all these individual measurements
becomes the total migration distance using Matlab.
by all cells beyond an initial starting location; this migration
index is used for statistical analysis (Figure 2).
C o l l a g e nt y p eI( I n v i t r o g e n )i su s e dt ofi l lt h ec h a n n e l
b e t w e e nc e n t r a la n ds i d ew e l l s ,a n di st h es u b s t r a t et h r o u g h
which cells migrate. Both 1mg/mL and 2mg/mL collagen
ca nbeu sed .Al th o u gh1m g / mLc o lla g e nr e s ul tsinso m ewh a t
higher nonspecific background cell chemokinesis and gel
loading is technically more difficult than with 2mg/mL
collagen, the lower collagen concentration permits greater
migration of primary cultures of SMC, and the assay sensi-
tivity is better. Unless otherwise specified, the concentration
of collagen in the migration channels was 1mg/mL for all
experiments.
2.7. Statistical Analysis. Statistical comparisons were made
using Student’s 𝑡-test or one-way ANOVA. Significance was
defined at the 𝑃 < 0.05 level.
3. Results and Discussion
AsshowninFigure 3(a),cellproliferationisblockedbyMMC
treatment. There is no significant difference in cell viability
between MMC-treated SMC (91.8 ± 4.0%) and untreated
SMC (93.0 ± 4.4%) for up to 48 hours after treatment.
Thus, cell accumulation in the various migration assays
represents true cell movement without any component of
cell proliferation. This is important because without MMC
treatment, migration indices from long-term incubations
may be confounded by coincident cellular proliferation.
In scratch assays (Figure 3(b))w i t hp r i m a r yS M Cc u l -
tures, cells randomly migrated (chemokinesis) to fill in the
defects at comparable rates regardless of PDGF concentra-
tion,includingintheabsenceofanychemotacticagent.With-
out MMC treatment, wound defects tend to close slightly
earlier, suggesting an element of cell proliferation.
Figure 3(c) shows the migration results for SMC using
the Boyden chamber transwell assay. The early (12h) time
point shows small but significantly increased migration in
response to 10–50ng/mL PDGF versus no chemokine in
the bottom well. However, there was no distinguishable
difference in migration over a 10 fold concentration range
of PDGF, suggesting that the assay is relatively insensitive,
at least for primary SMC cultures. Moreover, by 24 hours,
there are no differences among any of the concentrations of
chemokines (including the medium control) suggesting that
migration at this time point is nonspecific once the cytokine
concentrationshavebeguntoequilibratebetweenthetopand
bottom wells.
To formally demonstrate that migration across the mem-
brane in the upper well is not necessarily due to directed
chemotaxis,PDGFwasaddedtothetopwell,withorwithout
PDGF in the lower compartment. Even in the absence of
a chemokine gradient, PDGF in the upper chamber led to
markedly increased transmigration (Figure 3(d)); this can
only be attributed to increased chemokinesis.BioMed Research International 5
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Figure3:CellmigrationinscratchandBoydenchamberassays.(a)Mitomycin-C(MMC)inhibitionofSMCproliferation.SMCtreatedwithor
without MMC (40𝜇g/mL for 30min at 37
∘C) were plated in 6-well plates and subsequently harvested. Cell counts were manually performed
on a hemocytometer after 1h, 24h, and 48h; cell counts are expressed as the mean ± one standard deviation of triplicates. Trypan blue
exclusion showed no differences in cell viability over 48hr (91.8 ± 4.0%). MMC treatment leads to stable numbers of cells collected at 24h
and 48h with significantly increased proliferation in the non-MMC-treated populations (
∗∗𝑃 < 0.01). (b) Scratch assay; no differences are
seen in the extent of migration between cells cultured in no chemokine versus 25–100ng/mL PDGF; over the 3–6 hours of this assay, no
significant difference is seen between control cells and those treated with MMC. (c) Transwell assay; different concentrations of PDGF were
addedtothelowerchamberoftranswelldevicesattimezero;cellsontheloweraspectofthetranswellinsertwereenumeratedafter6h,12h,or
24h. Compared with no PDGF in the lower chamber, there were significantly greater cell numbers of migrated cells in 10ng/mL, 25ng/mL,
and 50ng/mL PDGF group after 12h (
∗𝑃 < 0.05). After 24 hours, migrated cell numbers in transwells with 5–50ng/mL PDGF were not
significantly different relative to chambers without PDGF. After 24 hours, migrated cell numbers when 100ng/mL PDGF was present in the
lower chamber were significantly reduced relative to the control 0ng/mL PDGF group. (d) Chemokinesis in transwells; the same 50ng/mL
concentration of PDGF was loaded into bottom chamber, top chamber, or both bottom and top chambers; cell migration was analyzed after
6h, 12h, or 24h. Relative to no PDGF in either chamber, cell migration was significantly greater with 50ng/mL in the lower chamber at 12
hours (
∗𝑃 < 0.05); by 24 hours, there was no significant difference between control chambers and 50ng/mL PDGF. Notably, adding PDGF
to the upper chamber, with or without PDGF in the lower chamber, led to significantly increased migration at 12 hours relative to PDGF in
the lower chamber alone (
∗𝑃 < 0.05).6 BioMed Research International
T
o
t
a
l
 
m
i
g
r
a
t
i
o
n
 
d
i
s
t
a
n
c
e
 
(
𝜇
m
)
60000
40000
20000
0
M
M
C
t
r
e
a
t
e
d
N
o
n
-
M
M
C
t
r
e
a
t
e
d
M
M
C
t
r
e
a
t
e
d
N
o
n
-
M
M
C
t
r
e
a
t
e
d
M
M
C
t
r
e
a
t
e
d
N
o
n
-
M
M
C
t
r
e
a
t
e
d
M
M
C
t
r
e
a
t
e
d
N
o
n
-
M
M
C
t
r
e
a
t
e
d
M
M
C
t
r
e
a
t
e
d
N
o
n
-
M
M
C
t
r
e
a
t
e
d
M
M
C
t
r
e
a
t
e
d
N
o
n
-
M
M
C
t
r
e
a
t
e
d
0PDGF
5PDGF
25PDGF
10PDGF
50PDGF
100PDGF
∗∗
∗∗
∗∗
∗∗ ∗∗
(a)
T
o
t
a
l
 
m
i
g
r
a
t
i
o
n
 
(
𝜇
m
)
20000
15000
10000
5000
0
0–50 0–2.5 2.5–50 2.5-2.5
∗
∗
(b)
40000
30000
20000
10000
0
0–50
0–2.5
6 0 12 24 48 72
T
o
t
a
l
 
m
i
g
r
a
t
i
o
n
 
d
i
s
t
a
n
c
e
 
(
𝜇
m
)
(h)
(c)
Figure 4: Microfluidic device assay. (a) Dose-response curves with and without prior MMC treatment. MMC-treated and nontreated SMC
wereplacedinsidecellwells,withdifferentconcentrationsofPDGF(5ng/mL,10ng/mL,25ng/mL,50ng/mL,and100ng/mL)presentinthe
centralsourcewells.MigrationwasmeasuredafterHoechst33342stainingandfluorescencemicroscopyafter48h,usingtheMatlabprogram
to calculate total migration. Controls (SMC medium only) and every concentration of PDGF were evaluated in triplicate devices. Significant
d i ff e r e n c e sc a nb es e e nf r o m5n g / m Lt o1 0 0n g / m LP D G Fc o m p a r e dw i t ht h ec o n t r o l(
∗∗𝑃 < 0.01). (b) Chemokinesis versus chemotaxis in
microfluidic devices. MMC-treated SMC with or without 2.5ng/mL PDGF were plated in the central cell well; 2.5ng/mL or 50ng/mL PDGF
were added to the side source wells. With no PDGF present in the central cell well, the assay shows significantly greater total migration after
48h with 50ng/mL in the source well (“0–50”) versus 2.5ng/mL in the source well (“0–2.5”). The presence of 2.5ng/mL PDGF in the central
cell well leads to significantly greater total migration when there is a concentration gradient (“2.5–50”;
∗𝑃 < 0.05)a t t r i b u t a b l et oal o c a l
chemokinesis effect. In the absence of a gradient (“2.5–2.5”), there is a chemokinesis-associated migration which is significantly less than the
migration seen when a gradient is present (“0–2.5”;
∗𝑃 < 0.05). (c) Time-course experiment performed as panel (b).
The transwell experiments, thus, suggest that although
initial PDGF concentration differences can induce some
degree of increased cell migration towards higher concentra-
tions in the lower wells, subsequent PDGF diffusion leads to
random chemokinesis.
In comparison, dose-response experiments using the
microfluidic devices (Figure 4) demonstrate significant
chemotaxis at concentrations as low as 2.5ng/mL PDGF
(Figure 4(b)), and show a dose-dependent increase in
chemotaxis with a peak of approximately 25–50ng/mLBioMed Research International 7
(Figure 4(a)). Interestingly, higher concentrations of PDGF
(e.g., 100ng/mL) lead to less migration, consistent with a
high-dose chemotaxis arrest (18). Of note, without prior
MMC treatment, the migration index is greater (Figure 4(a)),
highlighting the nonnegligible contribution of proliferation
to “apparent” chemotaxis occurring with longer assay times.
The results demonstrate that the microfluidic device for
measuring chemotaxis is substantially more sensitive than
the existing scratch or “gold standard” Boyden chamber
approaches.
Not only can the microfluidic device be used for mea-
suring chemotaxis, but also it can specifically distinguish the
contributions of chemokinesis and chemotaxis to migration
(Figure 4(b)). Thus, in the absence of a chemokine gradient
(e.g., 2.5ng/mL PDGF in both center and side wells), the
migration index reflects chemokinesis. In comparison, with
no PDGF in the center well and 2.5ng/mL in the side
well, the migration index reflects directed chemotaxis. The
microfluidicdevicecanalsoassesschemotaxisinthepresence
of existing chemokinesis, as when the center well contains
2.5ng/mL PDGF and the side well contains 50ng/mL. There
isasmallbutstatisticallygreatermigrationwhenthestimulus
is a chemotactic gradient rather than simple chemokinesis.
Since the chemokine gradient is established within 2
hours (17), and is stable for several days, cells can con-
tinuously migrate up the concentration gradient over time
(Figure 4(c)). In comparison, other classic methods either
have no concentration gradient (scratch assay) or only have a
transient chemokine gradient, so that chemokinesis—rather
than directed chemotaxis—is increasingly contributory.
The microfluidic device reported in this work is supe-
rior in a number of respects compared with other in
vitro approaches previously used to study chemotaxis. In
particular, the Boyden chamber—involving a chemokine
gradient across a porous membrane—has been a standard
chemotactic assay since the 1950s. However, this device has
significant limitations in that gradients are neither stable
nor linear, with an initial sharp concentration step up that
progressively deteriorates over time. More recently micro-
electromechanicalsystems(MEMS)technologiesweredevel-
oped that utilize microfluidic biochips to mimic in vivo
conditions; in these devices, cells are continually exposed to
shear forces under controlled flow. However, the continuous
flow of these devices presents a challenge to the maintenance
of stable chemokine gradients. Although hydrogels between
the source and sink channel can create linear concentration
gradients [18–20], subtle variations in the wells and channels
can engender pressure gradients that disrupt the gradients
t h r o u g hi n t e r s t i t i a lfl o w[ 21, 22]; moreover, the continuous
flow of the devices tends to dilute any chemoattractants
secreted by cell sources. In the novel microfluidic device
described previously [17] and validated for smooth muscle
cell migration in this paper, large volume source and sink
wells maintain stable chemokine gradients in the connecting
hydrogel; any interstitial flow is eliminated by connecting the
sourceandsinkwellswithadditionalchannelsandreservoirs
that serve as a resistor-capacitor circuit. The concentration
gradientsare,thus,stableandlinearforseveraldays.Thecur-
rent work has further refined the application, incorporating
mitomycin-Ctreatmenttoreduceanyconfoundingcontribu-
tion of proliferation and demonstrating how chemotaxis and
chemokinesiscanbeassessedinthesameexperimentalsetup.
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